BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
June 23, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021
June 22, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces European Patent Office Decision to Grant Patent on Autologous Cell Therapy Patient Selection Diagnostic Assay
June 21, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia to Be Added to the Russell Microcap® Index
June 14, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies,...
BioCardia to Present at the LD Micro Virtual Invitational Conference on June 8, 2021
June 02, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies,...
BioCardia Reports First Quarter 2021 Financial Results and Business Highlights
May 13, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies,...
BioCardia Signs Agreement with Leading Japanese Biotechnology Company for Catheter Biotherapeutic Delivery Product Candidates
April 26, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese biotechnology company related to...
BioCardia Reports 2020 Financial Results and Recent Business Highlights
March 30, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative...
BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
March 15, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces...
BioCardia Signs Agreement With Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates
February 23, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese pharmaceutical company related to...